5 states targeting Medicaid behavioral health enrollment amid fraud concerns
Impact on your practice
These enrollment freezes directly impact therapists seeking to enroll in Medicaid or expand existing practices. States are tightening credential verification and may require additional documentation. Established providers should expect heightened scrutiny and compliance audits.
Key facts
At least 5 states have implemented or extended temporary moratoriums on new Medicaid behavioral health provider enrollments
Indiana imposed 6-month moratorium on new ABA provider agency enrollments (effective June 6, 2026), approved by CMS
Maryland extended suspension on psychiatric rehabilitation, partial hospital, and intensive outpatient programs in 10 jurisdictions through July 1, 2026
Part of Trump administration's broader healthcare fraud crackdown (DOJ charged 455 people June 25, including 90 medical professionals)
States affected
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
How State Medicaid Uncertainties Are Reshaping the SUD Treatment Environment
While federal rates hold steady, state-level Medicaid administration is creating new operational burdens. Therapists face unpredictable coverage disruptions for patients, requiring care coordination infrastructure. This is reshaping hiring, staffing models, and clinical operations—particularly in rural/underserved regions where Medicaid dominates payer mix.
Arizona behavioral health clinic suspended from Medicaid amid fraud allegations
This case demonstrates escalating Medicaid compliance scrutiny and fraud investigations. Therapists should ensure meticulous documentation practices, avoid AI-generated notes, and understand that billing discrepancies can trigger multi-agency investigations. Fraud enforcement is intensifying.
Once-Fast-Growing Stepping Stones Behavioral Solutions Shutters
This high-profile provider collapse, despite commanding premium Medicaid rates, demonstrates that even generous reimbursement cannot offset systemic pressures: workforce shortages, regulatory burden, and operational complexity. Therapists should view this as a warning about sector sustainability and evaluate their own practice's financial resilience.
Maryland expands pharmacist scope to include opioid use disorder treatment
This expansion of pharmacist authority in OUD treatment affects therapists' competitive positioning and collaborative care model design. Therapists should understand that pharmacists now have direct prescribing authority for buprenorphine in Maryland, potentially reducing reliance on physicians and creating new inter-professional boundaries. For practices treating OUD, this changes referral patterns and may increase need for clear role definition in collaborative teams.